IPO - ArriVent BioPharma, Inc.

Form Type: 8-K

Filing Date: 2025-07-02

Corporate Action: Ipo

Type: New

Accession Number: 000110465925065386

Filing Summary: On July 1, 2025, ArriVent BioPharma, Inc. entered into an underwriting agreement with Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., and Guggenheim Securities, LLC for a public offering of common stock. The company plans to sell 2,482,692 shares of its common stock at a price of $19.50 per share and pre-funded warrants for an additional 1,363,469 shares at a price of $19.4999 each. The total gross proceeds anticipated from this offering are approximately $75 million before deducting underwriting commissions and expenses. The underwriters also have an option to purchase an additional 576,923 shares within 30 days. The offering is expected to close on July 3, 2025, subject to customary conditions. The offering will be conducted under the company's automatic shelf registration statement, which was declared effective on February 3, 2025. A press release announcing the pricing of the offering was issued on July 1, 2025, with a final prospectus supplement to be filed on July 2, 2025.